Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from the National Medical Products Administration (NMPA). One trial will test the combination of HRS-4357 with ADT and a novel androgen receptor pathway inhibitor for prostate cancer. The other trial will assess SHR-4602 in combination with SHR-A1811, or in combination with SHR-A1811 plus adebrelimab, or in combination with SHR-A1811, adebrelimab, and SHR-8068 for advanced solid tumors.
HRS-4357: A Radiotherapeutic Drug for Prostate Cancer
The Category 1 chemical HRS-4357, a radiotherapeutic drug, was previously cleared for a study in prostate specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC) in patients who had previously received androgen receptor (AR) pathway inhibitor and taxane therapy. HRS-4357 has no comparable drug approved globally, making it a potentially groundbreaking treatment.
SHR-4602 and SHR-A1811: Targeting HER2 in Cancer Treatments
SHR-4602 and SHR-A1811 are antibody drug conjugates (ADCs) targeting HER2, under development for the treatment of various cancers. These ADCs represent an innovative approach to cancer therapy, specifically designed to deliver potent cytotoxic payloads to cancer cells expressing HER2.
Adebrelimab and SHR-8068: Enhancing Cancer Immunotherapy
Adebrelimab, a programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb), was approved in China for the treatment of first-line extensive stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy in March of the previous year. SHR-8068 is an in-licensed CTLA-4 mAb, adding to the company’s portfolio of immunotherapeutic agents.-Fineline Info & Tech
